Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy
Trial Parameters
Brief Summary
This study is a multicenter, randomized phase II clinical study to evaluate Efficacy and safety, while observing pharmacokinetic profiles, pharmacodynamic effects, and immunogenicity of CM338 in subjects with Immunoglobulin A(IgA) nephropathy.
Eligibility Criteria
Inclusion Criteria: * Male or female aged 18-75. * Understand the nature of the study and sign the Informed Consent Form voluntarily. * Take effective contraception measures throughout the study period. Exclusion Criteria: * Used other investigational drugs within 30 days before the first study administration. * With previous history of Human immunodeficiency virus(HIV) infection. * Treponema pallidum antibody positive in screening period. * May have active Mycobacterium tuberculosis infection. * Major surgery is planned during the study. * Other reasons the investigator believes that the subject is not suitable to participate in this study.